These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Glioblastoma biomarkers from bench to bedside: advances and challenges. Farias-Eisner G; Bank AM; Hwang BY; Appelboom G; Piazza MA; Bruce SS; Sander Connolly E Br J Neurosurg; 2012 Apr; 26(2):189-94. PubMed ID: 22176646 [TBL] [Abstract][Full Text] [Related]
5. Advances and challenges in the treatment of glioblastoma: a clinician's perspective. Mrugala MM Discov Med; 2013 Apr; 15(83):221-30. PubMed ID: 23636139 [TBL] [Abstract][Full Text] [Related]
6. A systematic review of multifocal and multicentric glioblastoma. Li Y; Zhang ZX; Huang GH; Xiang Y; Yang L; Pei YC; Yang W; Lv SQ J Clin Neurosci; 2021 Jan; 83():71-76. PubMed ID: 33358091 [TBL] [Abstract][Full Text] [Related]
7. From imaging to biology of glioblastoma: new clinical oncology perspectives to the problem of local recurrence. Zygogianni A; Protopapa M; Kougioumtzopoulou A; Simopoulou F; Nikoloudi S; Kouloulias V Clin Transl Oncol; 2018 Aug; 20(8):989-1003. PubMed ID: 29335830 [TBL] [Abstract][Full Text] [Related]
8. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Chinot OL; de La Motte Rouge T; Moore N; Zeaiter A; Das A; Phillips H; Modrusan Z; Cloughesy T Adv Ther; 2011 Apr; 28(4):334-40. PubMed ID: 21432029 [TBL] [Abstract][Full Text] [Related]
9. Recent and ongoing clinical trials in glioblastoma. Lombardi G Clin Adv Hematol Oncol; 2018 Jul; 16(7):480-483. PubMed ID: 30067618 [No Abstract] [Full Text] [Related]
10. Personalized regulation of glioblastoma cancer stem cells based on biomedical technologies: From theory to experiment (Review). Bryukhovetskiy I; Ponomarenko A; Lyakhova I; Zaitsev S; Zayats Y; Korneyko M; Eliseikina M; Mischenko P; Shevchenko V; Shanker Sharma H; Sharma A; Khotimchenko Y Int J Mol Med; 2018 Aug; 42(2):691-702. PubMed ID: 29749540 [TBL] [Abstract][Full Text] [Related]
11. Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments. Kesari S Semin Oncol; 2011 Dec; 38 Suppl 4():S2-10. PubMed ID: 22078644 [TBL] [Abstract][Full Text] [Related]
12. Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors. Schäfer N; Gielen GH; Rauschenbach L; Kebir S; Till A; Reinartz R; Simon M; Niehusmann P; Kleinschnitz C; Herrlinger U; Pietsch T; Scheffler B; Glas M J Transl Med; 2019 Mar; 17(1):96. PubMed ID: 30894200 [TBL] [Abstract][Full Text] [Related]
13. Present and Future of Anti-Glioblastoma Therapies: A Deep Look into Molecular Dependencies/Features. Kim HJ; Kim DY Molecules; 2020 Oct; 25(20):. PubMed ID: 33053763 [TBL] [Abstract][Full Text] [Related]
14. Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): an integrated multidisciplinary commentary. Jarzabek MA; Sweeney KJ; Evans RL; Jacobs AH; Stupp R; O'Brien D; Berger MS; Prehn JH; Byrne AT Drug Discov Today; 2013 Nov; 18(21-22):1052-66. PubMed ID: 23792334 [TBL] [Abstract][Full Text] [Related]
15. Glioblastoma multiforme: a review of therapeutic targets. Kanu OO; Mehta A; Di C; Lin N; Bortoff K; Bigner DD; Yan H; Adamson DC Expert Opin Ther Targets; 2009 Jun; 13(6):701-18. PubMed ID: 19409033 [TBL] [Abstract][Full Text] [Related]